Next-Generation Gynecological Cancer Diagnostics Market Will Reach USD 5,135 Million by 2030 | P&S Intelligence

In 2022, the global next-generation gynecological cancer diagnostics market had a total size of USD 2,396 million, and it is projected to hit USD 5,135 million by 2030, progressing at a rate of 10% from 2022 to 2030, according to a research report by a market research company P&S Intelligence.

This growth can be credited to the growing occurrence of gynecological malignancies, variations in lifestyle and overweightness in women, growing cases of menopause issues, and the increasing occurrence of diabetes. Moreover, a bad diet and extreme consumption of soy products, flaxseeds, and Vitamin D are accountable for high estrogen levels in the body that sources cancer.

Download sample pages of this report: https://www.psmarketresearch.com/market-analysis/next-generation-gynecological-cancer-diagnostics-market/report-sample

Cervicovaginal human papillomavirus is one of the most generally affected sexually communicated illnesses in both women and men, which primarily causes cervical and other solid tumors (vaginal, vulvar). Around 200 genetic kinds have been discovered, and they are segmented into the high-risk genotype and low-risk genotype, on the basis of their carcinogenic nature.

Furthermore, it has been confirmed that persistent infection with the risky papillomavirus genotype is a key factor for cervical cancer and cervical precancerous abrasions, even though condyloma acuminatum or hyperplastic lesions is associated with the low-risk genotype.

In 2022, the next-generation sequencing category held the largest market share, and the category is projected to be dominant throughout the forecast period. This is mainly because of the potential of NGS to detect genetic change that is actionable with targeted treatment. NGS has a chance of 33.4% in recognizing gynecologic cancers and a high medical action rate.

Make inquiry before purchase of this report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=next-generation-gynecological-cancer-diagnostics-market

With the excessive clinical utility of NGS, testing also appeared to advance survival for people who got targeted treatment. Moreover, NGS plays a vital role in tumor study and has permitted unparalleled growth of solid tumors' molecular profiling.

In 2022, the uterine cancer category held the largest next-generation gynecological cancer diagnostics market share, of above 30%, and the category is projected to be dominant throughout the forecast period.

This can be credited to the growing cases of uterine cancer worldwide, because of the rising aging women populace, rising menopause problems after the age of 55, the growing occurrence of high blood sugar levels and blood pressure, and growing situations of obesity and high estrogen levels.

Browse full report at: https://www.psmarketresearch.com/market-analysis/next-generation-gynecological-cancer-diagnostics-market

In 2022, North America dominated the industry with the largest market share, of above 40%, and the continent is projected to be dominant throughout the forecast period. This is mainly because of the growing cases of cervical and gynecological malignancies in the continent. These are very stressful situations and aid in the acceptance of diagnosis methods.

Hence, the growing occurrence of gynecological malignancies, variations in lifestyle and overweightness in women, growing cases of menopause issues, and the increasing occurrence of diabetes are the major factors propelling the market.

Next-Generation Gynecological Cancer Diagnostics Market Size Breakdown by Segment

By Technology
• Polymerase Chain Reaction (PCR)
• Next-Generation Sequencing (NGS),
• DNA Microarrays
• Others
By Cancer Type
• Cervical Cancer
• Ovarian Cancer
• Uterine Cancer
• Vaginal Cancer
• Vulvar Cancer
By Function
• Therapeutic Monitoring
• Companion Diagnostics
• Prognostics
• Cancer Screening
• Risk Analysis
• Others
By End User
• Hospitals and Ambulatory Centers
• Diagnostic Laboratories
• Academic and Research Institutes
• Others
By Region
• North America Next-Generation Gynecological Cancer Market
o By technology
o By cancer type
o By function
o By end user
o By country - U.S. and Canada
• Europe Next-Generation Gynecological Cancer Market
o By technology
o By cancer type
o By function
o By end user
o By country - Germany, U.K., France, Italy, Spain, and Rest of Europe
• Asia-Pacific (APAC) Next-Generation Gynecological Cancer Market
o By technology
o By cancer type
o By function
o By end user
o By country - Japan, China, India, South Korea, Australia, and Rest of APAC
• Latin America (LATAM) Next-Generation Gynecological Cancer Market
o By technology
o By cancer type
o By function
o By end user
o By country - Brazil, Mexico and Rest of LATAM
• Middle East and Africa (MEA) Next-Generation Gynecological Cancer Market
o By technology
o By cancer type
o By function
o By end user
o By country - Saudi Arabia, South Africa, U.A.E., and Rest of MEA

Contact:
Chandra Mohan
AVP - Business Development
Phone: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
Blog: https://psintelligence.blogspot.com

About P&S Intelligence

P&S Intelligence offers custom and syndicated market research and consulting services to clients across the globe. Our team of young and dynamic researchers, guided by mentors with years of experience, create data-rich reports tailored to the needs of MNCs as well as startups and SMEs. We remain in a perennial quest to offer exhaustive insights into every aspect of the market, allowing businesses of all sizes to seize even the smallest of opportunities and tackle even the biggest of challenges.

This release was published on openPR.